(Q38112184)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

title

Novel approaches to glioma drug design and drug screening (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

0 references

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

Shivaputra A Patil

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Amira Hosni-Ahmed

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Terreia S Jones

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Renukadevi Patil

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

Duane D Miller

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

6 June 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

1135-1151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009.

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Malignant astrocytic glioma: genetics, biology, and paths to treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

The origins of glioma: E Pluribus Unum?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Drug delivery to brain tumours: challenges and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 and GST-pi in human glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Chemotherapy resistance of glioblastoma stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Current issues in ER and HER2 testing by IHC in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Intravenous carboplatin for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

A phase II study of intravenous carboplatin for the treatment of recurrent gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Neuro-oncology: the growing role of chemotherapy in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

21 January 2018

Erlotinib hydrochloride

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase II trial of gefitinib in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Designer therapies for glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Review camptothecin: current perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Experience with irinotecan for the treatment of malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Concurrent twice-a-week docetaxel and radiotherapy: a dose escalation trial with immunological toxicity evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Overcoming multidrug resistance in taxane chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Identification of compounds selectively killing multidrug-resistant cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Cannabinoids for cancer treatment: progress and promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Antiglioma action of xanthones from Gentiana kochiana: Mechanistic and structure-activity requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

New substituted 4H-chromenes as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

8-Hydroxynaphthalene-1,4-dione derivative as novel compound for glioma treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(py

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Design and synthesis of novel 3,4-disubstituted pyrazoles for nanomedicine applications against malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Screening of anti-cancer agent using zebrafish: comparison with the MTT assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Application of the MTT assay to human prostate cancer cell lines in vitro: establishment of test conditions and assessment of hormone-stimulated growth and drug-induced cytostatic and cytotoxic effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Thiopurine methyltransferase predicts the extent of cytotoxicty and DNA damage in astroglial cells after thioguanine exposure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

A novel high-through-put assay for screening of pro-apoptotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Live-cell imaging of caspase activation for high-content screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Identification of novel autophagy regulators by a luciferase-based assay for the kinetics of autophagic flux

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Psammaplin A as a general activator of cell-based signaling assays via HDAC inhibition and studies on some bromotyrosine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Impact of high-throughput screening in biomedical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Virtual screening methods that complement HTS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

High-throughput kinase profiling as a platform for drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

The hollow fibre model in cancer drug screening: the NCI experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Correlative effect between in vivo hollow fiber assay and xenografts assay in drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Targeting glioma stem cells by functional inhibition of a prosurvival oncomiR-138 in malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Stem-like tumor-initiating cells isolated from IL13Rα2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

The central nervous system-restricted transcription factor Olig2 opposes p53 responses to genotoxic damage in neural progenitors and malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

53BP1 is a haploinsufficient tumor suppressor and protects cells from radiation response in glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Radiation and drug response of the rat glioma RG2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Analysis of tissue chimerism in nude mouse brain and abdominal xenograft models of human glioblastoma multiforme: what does it tell us about the models and about glioblastoma biology and therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Excited-state proton transfer and the mechanism of action of firefly luciferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Transgenic nude mouse with ubiquitous green fluorescent protein expression as a host for human tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

The multistep nature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Glioblastoma models reveal the connection between adult glial progenitors and the proneural phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Modeling Adult Gliomas Using RCAS/t-va Technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Genetic pathways to glioblastoma: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Perifosine inhibits multiple signaling pathways in glial progenitors and cooperates with temozolomide to arrest cell proliferation in gliomas in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Drug resistance in glioblastoma: a mini review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Treatment resistance mechanisms of malignant glioma tumor stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

Selective inhibition of tumor oncogenes by disruption of super-enhancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.807248

10.1517/17460441.2013.807248

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23738794%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference